Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
BRCA1/2 mutation carriers
Breast cancer
Cardiopulmonary fitness
Lifestyle intervention
Nutrition
Physical activity
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
11
2020
accepted:
23
12
2020
pubmed:
6
2
2021
medline:
24
6
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
Germline BRCA1/2 mutation carriers (gBMC) face increased cancer risks that are modulated via non-genetic lifestyle factors whose underlying molecular mechanisms are unknown. The peptides Neurotensin (NT) and Enkephalin (ENK)-involved in tumorigenesis and obesity-related diseases-are of interest. We wanted to know whether these biomarkers differ between gBMC and women from the general population and what effect a 1-year lifestyle-intervention has in gBMC. The stable precursor fragments pro-NT and pro-ENK were measured at study entry (SE), after 3 and 12 months for 68 women from LIBRE-1 (a controlled lifestyle-intervention feasibility trial for gBMC involving structured endurance training and the Mediterranean Diet). The SE values were compared with a cohort of the general population including female subjects with and without previous cancer disease, non-suggestive for hereditary breast and ovarian cancer (OMA-reference). For LIBRE-1, we analysed the association between the intervention-related change in the two biomarkers and certain lifestyle factors. At SE, gBMC had a higher median pro-NT than OMA-reference (in the subgroups with previous cancer 117 vs. 91 pmol/L, p = 0.002). Non-diseased gBMC had lower median pro-ENK levels when compared to the non-diseased reference group. VO2peak and pro-NT 1-year change in LIBRE-1 were inversely correlated (r = - 0.435; CI - 0.653 to - 0.151; p = 0.004). Pro-ENK correlated positively with VO2peak at SE (r = 0.323; CI 0.061-0.544; p = 0.017). Regression analyses showed an inverse association of 1-year changes for pro-NT and Omega-6/Omega-3 (Estimate: - 37.9, p = 0.097/0.080) in multivariate analysis. Our results give first indications for lifestyle-related modification particularly of pro-NT in gBMC.
Sections du résumé
BACKGROUND
BACKGROUND
Germline BRCA1/2 mutation carriers (gBMC) face increased cancer risks that are modulated via non-genetic lifestyle factors whose underlying molecular mechanisms are unknown. The peptides Neurotensin (NT) and Enkephalin (ENK)-involved in tumorigenesis and obesity-related diseases-are of interest. We wanted to know whether these biomarkers differ between gBMC and women from the general population and what effect a 1-year lifestyle-intervention has in gBMC.
METHODS
METHODS
The stable precursor fragments pro-NT and pro-ENK were measured at study entry (SE), after 3 and 12 months for 68 women from LIBRE-1 (a controlled lifestyle-intervention feasibility trial for gBMC involving structured endurance training and the Mediterranean Diet). The SE values were compared with a cohort of the general population including female subjects with and without previous cancer disease, non-suggestive for hereditary breast and ovarian cancer (OMA-reference). For LIBRE-1, we analysed the association between the intervention-related change in the two biomarkers and certain lifestyle factors.
RESULTS
RESULTS
At SE, gBMC had a higher median pro-NT than OMA-reference (in the subgroups with previous cancer 117 vs. 91 pmol/L, p = 0.002). Non-diseased gBMC had lower median pro-ENK levels when compared to the non-diseased reference group. VO2peak and pro-NT 1-year change in LIBRE-1 were inversely correlated (r = - 0.435; CI - 0.653 to - 0.151; p = 0.004). Pro-ENK correlated positively with VO2peak at SE (r = 0.323; CI 0.061-0.544; p = 0.017). Regression analyses showed an inverse association of 1-year changes for pro-NT and Omega-6/Omega-3 (Estimate: - 37.9, p = 0.097/0.080) in multivariate analysis.
CONCLUSION
CONCLUSIONS
Our results give first indications for lifestyle-related modification particularly of pro-NT in gBMC.
Identifiants
pubmed: 33543354
doi: 10.1007/s10549-020-06070-x
pii: 10.1007/s10549-020-06070-x
pmc: PMC8019429
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Enkephalins
0
Neurotensin
39379-15-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
741-752Subventions
Organisme : Deutsche Krebshilfe
ID : Grant no. 110013
Références
JAMA. 2006 Jul 12;296(2):193-201
pubmed: 16835425
Endocrinology. 2016 Sep;157(9):3482-92
pubmed: 27580810
Ecancermedicalscience. 2015 Jul 23;9:557
pubmed: 26284121
Lancet Diabetes Endocrinol. 2018 Feb;6(2):95-104
pubmed: 29195904
Int Immunopharmacol. 2016 Aug;37:59-64
pubmed: 26927200
World J Gastroenterol. 2014 Mar 7;20(9):2218-23
pubmed: 24605021
BMC Cancer. 2017 Nov 10;17(1):752
pubmed: 29126396
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2253-2260
pubmed: 29590379
Clin Nutr. 2020 Aug;39(8):2389-2398
pubmed: 31735538
Med Res Rev. 2016 Sep;36(5):871-923
pubmed: 27197922
Pilot Feasibility Stud. 2016 Dec 19;2:74
pubmed: 28031860
Clin Biochem. 2018 Aug;58:72-77
pubmed: 29782819
Brain Res Brain Res Rev. 2002 Feb;38(3):351-76
pubmed: 11890982
BMC Med. 2014 Jul 24;12:112
pubmed: 25055810
J Am Soc Nephrol. 2017 Jan;28(1):291-303
pubmed: 27401687
Biomark Med. 2019 Sep;13(13):1107-1117
pubmed: 31468986
Trials. 2016 Jul 29;17:368
pubmed: 27473440
JAMA. 2017 Nov 28;318(20):1975-1976
pubmed: 28973170
Nutrients. 2019 Sep 02;11(9):
pubmed: 31480794
Clinics (Sao Paulo). 2011;66(1):151-7
pubmed: 21437452
Breast Cancer Res. 2012 Feb 20;14(1):R33
pubmed: 22348646
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6
pubmed: 24925674
Peptides. 2015 Feb;64:74-81
pubmed: 25582563
J Immunol. 1979 Sep;123(3):1068-70
pubmed: 224107
J Endocrinol Invest. 2018 Oct;41(10):1159-1163
pubmed: 29417469
Arch Gynecol Obstet. 2017 Dec;296(6):1135-1144
pubmed: 28975393
Nat Med. 2013 Oct;19(10):1252-63
pubmed: 24100998
Maturitas. 2016 Sep;91:135-9
pubmed: 27451331
Menopause. 2017 Mar;24(3):322-344
pubmed: 27779567
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1692-7
pubmed: 27312221
JAMA. 2012 Oct 10;308(14):1469-75
pubmed: 23047361
Toxicol Appl Pharmacol. 2018 Nov 15;359:12-23
pubmed: 30222981
Curr Probl Cardiol. 2021 Mar;46(3):100421
pubmed: 31558344
Circulation. 2012 Oct 30;126(18):2261-74
pubmed: 22952317
Nature. 2015 Mar 12;519(7542):242-6
pubmed: 25533952
Lancet Oncol. 2017 Aug;18(8):e457-e471
pubmed: 28759385
Life Sci. 2019 Aug 15;231:116542
pubmed: 31176781
J Clin Oncol. 2015 Aug 20;33(24):2632-8
pubmed: 26169618
Nature. 2016 May 11;533(7603):411-5
pubmed: 27193687
Cancer Res. 2001 Jul 15;61(14):5420-4
pubmed: 11454686
J Cardiovasc Pharmacol Ther. 2018 Jul;23(4):279-291
pubmed: 29528698
Front Endocrinol (Lausanne). 2013 Mar 22;4:36
pubmed: 23526754
Recent Results Cancer Res. 2011;188:125-39
pubmed: 21253795
Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H402-8
pubmed: 17951371
Exp Biol Med (Maywood). 2013 May;238(5):579-87
pubmed: 23856908
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558